e21064 Background: Breast cancer (BC) is an heterogeneous disease and the most common cause of cancer death in Uruguayan women. HER2 and hormone receptors (HR) tumor expression define BC subtypes with different prognosis and characteristics. We previously classified BC in the following subtypes: HR+/HER2-, triple negative (TN), HER2+ and reported their relation with clinical and pathologic features. The purpose of this study was to analyze the relationship between these biological subtypes and disease free survival (DFS) in Uruguayan BC patients (pts). Methods: We retrospectively reviewed clinical records from pts who underwent curative surgery for stage I-III invasive BC at the Oncology Units of 4 institutions in Montevideo, Uruguay, between March 2006 and March 2008. HR and HER2 status were assessed by immunohistochemistry (IHC). DFS was estimated using the Kaplan-Meier method and compared across groups using log rank statistics. Results: 169 pts were included ; median follow up was 43 months. At the time of the analysis 160 pts (94.7%) were alive and 141 (83.4%) free of relapse. One hundred and twenty three pts were HR+/HER 2 – (72,7%), 32 pts were TN (18.9%) and 14 pts were HER2 + (8.2%). Two-year DFS was 93.3%, 94% for HR+/HER2 -, 91% for TN and 71.4% for HER2+. HER2 + pts had a shorter DFS than HR+/HER 2- (p=0.03) and TN pts (p=0.11). The median survival was not reached for all the pts nor for any of the subgroups. Conclusions: In accordance with international reports our results indicate that HER 2+ pts have shorter DFS. The overlapping DFS curves and similar two-year DFS of HR+/HER2- and TN pts were not explained by the clinical and pathologic differences.

e11622 Background: Hereditary BC can have a distinct phenotype and behavior in comparison to sporadic BC. The aim of the present study was to investigate if there is any difference in the age at diagnosis, disease extension and biological profile in BC patients (pts) with or without a significant family history of BC. METHODS We retrospectively reviewed clinical charts of BC pts, stage 0- III who had surgery between March 2006 and March 2008. We included pts with known estrogen receptor (ER), progesterone receptor (PR) and HER2 status. The family history was obtained from the clinical charts and confirmed by a telephone interview with a standardized questionnaire. A significant family history of BC was defined by the presence of one of the following criteria: (1) 3 or more BC cases among close relatives, at least one diagnosed before 50 years (2) 2 BC cases among close relatives, at least one diagnosed before 50 years and one of the following: bilateral BC, ovarian cancer diagnosed in the family, male BC, father´s inheritance, Ashkenazi Jewish ancestry Results: 435 pts were identified, with available data on ER/PR and HER2 status in 197 pts. Family history was evaluated in 136 pts (69%) and was classified as significant in 18 (13.2%). Between pts with and without a significant family history of BC cancer there were no difference in the proportion of pts < 50 years old at diagnosis (0.36 vs. 0.39), T3/T4 tumours (0.08 vs. 0.11), axillary node positivity (0.55 vs 0.66), ER/PR+ (0.77 vs. 0.72), HER2 + (0.11 vs. 0.11) and triple negative tumors (0.19 vs 0.17). CONCLUSIONS our data does not show any difference in the main prognostic and predictive factors between operable BC pts with and without a significant family history of BC. These findings are concordant with previous published data about a greater prevalence of BRCA2 mutations in Uruguayan families. No significant financial relationships to disclose.

We discuss the clinical presentation and course of the disease of a 25-year-old male who had gastrointestinal (GIT) symptoms secondary to retroperitoneal lymph node proliferation of a germ-cell tumour of the testis. The pathology evaluation of the orchiectomy specimen classified it as a burned-out tumour of the testis, given the lack of tumour elements and the presence of typical scarring tissue. Biological is-sues leading to tumour regression are discussed, as well.